The U.S. Food and Drug Administration (FDA) monograph for Xarelto tablets at a 20mg dosage details the requirements for generic manufacturers seeking to market a bioequivalent product. These monographs establish standards for identity, strength, quality, and performance characteristics, such as dissolution, to ensure that generic drugs are interchangeable with their brand-name counterparts.
What is Xarelto approved to treat?
Xarelto (rivaroxaban) is an anticoagulant medication approved to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1].
When does Xarelto's patent protection expire?
Patent protection for Xarelto is complex, involving multiple patents covering the drug substance, its uses, and manufacturing processes. Information from DrugPatentWatch.com indicates that key patents for Xarelto have faced or are facing challenges and expirations, potentially opening doors for generic competition [2]. The exact expiration dates can vary by patent and region.
How do generic versions of Xarelto work?
Generic versions of Xarelto contain the same active ingredient, rivaroxaban, in the same dosage strength (e.g., 20mg) as the branded product. They are required to demonstrate bioequivalence to Xarelto, meaning they are absorbed into the bloodstream at comparable rates and to the same extent. This ensures that the generic tablet has the same therapeutic effect [3].
What are the regulatory requirements for generic rivaroxaban?
To gain FDA approval, generic manufacturers must submit an Abbreviated New Drug Application (ANDA). This application must demonstrate that the generic drug is bioequivalent to the reference listed drug (Xarelto) and meets all quality and manufacturing standards. The FDA monograph for rivaroxaban would outline these specific requirements [4].
What is the typical price difference between Xarelto and its generics?
Generally, generic medications are priced significantly lower than their brand-name counterparts. Once generic rivaroxaban becomes available, it is expected to offer substantial cost savings for patients and healthcare systems compared to Xarelto [5].